Hodgkin’s disease (HD) is an uncommon malignancy accounting for an incidence of 0.6% of all cancers. In 2015, an estimated 9,050 people will be diagnosed with HD in the United States and 1,150 people will die from the disease . From 2007 to 2011, the incidence rates for HD have been stable but death rates have been steadily decreasing by 2.2% per year for men and 2.7% for women per year for women. The latter have been attributed to better therapeutic interventions. Once considered, the “inexorably fatal condition”, HD had long been a subject of controversy with respect to its nature, etiology and therapy. Initially thought to be an infectious disease due to its association with tuberculosis, definitive evidence of its neoplastic nature came in the 1960’s when cytogenetic studies confirmed its clonal derivation and aneuploidy.